Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
| Autor: | Ioannis N. Petropoulos, Hamad Almuhannadi, Osama Migahid, Amin Jayyousi, Marwan Ramadan, Ziyad Mahfoud, Adnan Khan, Georgios Ponirakis, Uazman Alam, Ayman Megahed, Hanadi Al Hamad, Ralph A. DeFronzo, Hoda Gad, Mona Hassan, Muhammad A. Abdul-Ghani, Rayaz A. Malik |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
diabetic neuropathies
Blood Glucose medicine.medical_specialty Diabetic neuropathy Endocrinology Diabetes and Metabolism medicine.medical_treatment Urology 030209 endocrinology & metabolism Type 2 diabetes Diseases of the endocrine glands. Clinical endocrinology Insulin aspart 03 medical and health sciences 0302 clinical medicine Glucagon-Like Peptide 1 Diabetes mellitus medicine Humans Hypoglycemic Agents Qatar Glycated Hemoglobin Pioglitazone Insulin glargine business.industry Venoms Insulin insulin glargine Emerging Technologies Pharmacology and Therapeutics RC648-665 medicine.disease Diabetes Mellitus Type 2 Exenatide sense organs business Peptides 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | BMJ Open Diabetes Research & Care BMJ OPEN DIABETES RESEARCH & CARE BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020) |
| ISSN: | 2052-4897 |
| Popis: | IntroductionTo assess the effect of exenatide and pioglitazone or basal-bolus insulin on diabetic peripheral neuropathy (DPN) in patients with poorly controlled type 2 diabetes (T2D).Research design and methodsThis is a substudy of the Qatar Study, an open-label, randomized controlled trial. 38 subjects with poorly controlled T2D were studied at baseline and 1-year follow-up and 18 control subjects were assessed at baseline only. A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c ResultsSubjects with T2D had reduced corneal nerves, but other DPN measures were comparable with the control group. In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (pConclusionsTreatment with exenatide and pioglitazone or basal-bolus insulin results in corneal nerve regeneration, but no change in neuropathic symptoms or sudomotor function over 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|